India&nbsp;has given emergency use authorization for a&nbsp;COVID-19&nbsp;antibody-drug&nbsp;cocktail&nbsp;developed by&nbsp;Roche&nbsp;and&nbsp;Regeneron, expanding its arsenal of drugs to battle a massive second wave of infections.

The decision was taken based on data filed with the US&nbsp;regulators and the scientific opinion of a European regulatory panel, Roche's India distribution partner for the drug, Cipla, said on Wednesday.

The therapy is a&nbsp;cocktail&nbsp;of two antibodies Casirivimab and Imdevimab, which are synthetically manufactured copies of antibodies that the body produces after an infection.

It has been shown to reduce hospitalizations in&nbsp;<a href="https://www.wionews.com/topics/coronavirus">COVID-19</a>&nbsp;patients who are at a high risk of developing severe illness.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/india-accounts-for-46-per-cent-of-worlds-new-covid-19-cases-quarter-of-deaths-who-382992">India accounts for 46 per cent of world's new COVID-19 cases, quarter of deaths: WHO</a>

The drug already has similar authorization in the United States and is used in Europe non-hospitalised patients. Former US&nbsp;President Donald Trump had taken the drug when he contracted the disease.

Cipla said the drug is meant for people with mild-to-moderate infection who are at high risk of developing severe disease. The company did not provide a price or a launch date.

In the last 10 days, more than 33,000&nbsp;Indians have died of&nbsp;COVID-19, with the country facing a severe shortage of&nbsp;COVID-19&nbsp;medicine including Gilead's remdesivir and&nbsp;Roche's tocilizumab.

Also read |&nbsp;<a href="https://www.wionews.com/world/regeneron-to-seek-us-approval-for-covid-19-cocktail-to-be-used-for-prevention-377212">Regeneron to seek US approval for COVID-19 cocktail to be used for prevention</a>

Both government and local manufacturers have said they are working to ramp up production. Smaller&nbsp;Indian drugmaker Natco Pharma said on Monday it received emergency use authorization for baricitinib, originally developed by Eli Lilly, to be used with remdesivir to&nbsp;treat&nbsp;COVID-19.

India's official tally of coronavirus infections has crossed 20 million and is second only to the United States. Deaths have reached 226,188, but experts say the real tally could be several times higher.

India has given emergency use authorization for a COVID-19 antibody-drug cocktail developed by Roche and Regeneron, expanding its arsenal of drugs to battle a massive second wave of infections.

India has given emergency use authorization for a COVID-19 antibody-drug cocktail developed by Roche and Regeneron, expanding its arsenal of drugs to battle a massive second wave of infections. The decision was taken based on data filed with the US regulators and the scientific opinion of a European regulatory panel, Roche's India distribution partner for the drug, Cipla, said on Wednesday. The therapy is a cocktail of two antibodies Casirivimab and Imdevimab, which are synthetically manufactured copies of antibodies that the body produces after an infection. It has been shown to reduce hospitalizations in COVID-19 patients who are at a high risk of developing severe illness. Also read | India accounts for 46 per cent of world's new COVID-19 cases, quarter of deaths: WHO The drug already has similar authorization in the United States and is used in Europe non-hospitalised patients. Former US President Donald Trump had taken the drug when he contracted the disease. Cipla said the drug is meant for people with mild-to-moderate infection who are at high risk of developing severe disease. The company did not provide a price or a launch date. In the last 10 days, more than 33,000 Indians have died of COVID-19, with the country facing a severe shortage of COVID-19 medicine including Gilead's remdesivir and Roche's tocilizumab. Also read | Regeneron to seek US approval for COVID-19 cocktail to be used for prevention Both government and local manufacturers have said they are working to ramp up production. Smaller Indian drugmaker Natco Pharma said on Monday it received emergency use authorization for baricitinib, originally developed by Eli Lilly, to be used with remdesivir to treat COVID-19. India's official tally of coronavirus infections has crossed 20 million and is second only to the United States. Deaths have reached 226,188, but experts say the real tally could be several times higher.

India approves Roche/Regeneron antibody cocktail to treat COVID-19

casirivimab-and-imdevimab

Casirivimab And Imdevimab, News on Casirivimab And Imdevimab, stories on Casirivimab And Imdevimab, articles on Casirivimab And Imdevimab, Casirivimab And Imdevimab stories at Wion, Casirivimab And Imdevimab news, Casirivimab And Imdevimab latest news

casirivimab and-imdevimab

India approves Roche/Regeneron antibody cocktail to treat COVID-19